Search

Your search keyword '"Dingemans, A.M."' showing total 17 results
Start Over Author "Dingemans, A.M."
17 results on '"Dingemans, A.M."'

1. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

Author

Passaro, A., primary, Leighl, N., additional, Blackhall, F., additional, Popat, S., additional, Kerr, K., additional, Ahn, M.J., additional, Arcila, M.E., additional, Arrieta, O., additional, Planchard, D., additional, de Marinis, F., additional, Dingemans, A.M., additional, Dziadziuszko, R., additional, Faivre-Finn, C., additional, Feldman, J., additional, Felip, E., additional, Curigliano, G., additional, Herbst, R., additional, Jänne, P.A., additional, John, T., additional, Mitsudomi, T., additional, Mok, T., additional, Normanno, N., additional, Paz-Ares, L., additional, Ramalingam, S., additional, Sequist, L., additional, Vansteenkiste, J., additional, Wistuba, I.I., additional, Wolf, J., additional, Wu, Y.L., additional, Yang, S.R., additional, Yang, J.C.H., additional, Yatabe, Y., additional, Pentheroudakis, G., additional, and Peters, S., additional

Published
2022
Full Text
View/download PDF

2. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Author

Garassino, M.C., Whisenant, J.G., Huang, L.C., Trama, A., Torri, V., Agustoni, F., Baena, J., Banna, G., Berardi, R., Bettini, A.C., Bria, E., Brighenti, M., Cadranel, J., Toma, A. De, Chini, C., Cortellini, A., Felip, E., Finocchiaro, G., Garrido, P., Genova, C., Giusti, R., Gregorc, V., Grossi, F., Grosso, F., Intagliata, S., Verde, N. La, Liu, S.V., Mazieres, J., Mercadante, E., Michielin, O., Minuti, G., Moro-Sibilot, D., Pasello, G., Passaro, A., Scotti, V., Solli, P., Stroppa, E., Tiseo, M., Viscardi, G., Voltolini, L., Wu, Y.L., Zai, S., Pancaldi, V., Dingemans, A.M., Meerbeeck, J. Van, Barlesi, F., Wakelee, H., Schuurbiers, O.C.J., Peters, S., Horn, L., RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, MUMC+: MA Med Staf Spec Longziekten (9), Pulmonary Medicine, TERAVOLT investigators, and TERAVOLT Investigators

Subjects
Male, 0301 basic medicine, medicine.medical_specialty, Aged, Betacoronavirus, Cause of Death, Coronavirus Infections, Cross-Sectional Studies, Female, Hospitalization, Humans, Longitudinal Studies, Middle Aged, Pandemics, Pneumonia, Viral, Registries, Risk Factors, Thoracic Neoplasms, COVID-19, Pneumonia, Viral, SARS-CoV-2, Article, 03 medical and health sciences, 0302 clinical medicine, Disease registry, Intensive care, Internal medicine, medicine, Medical history, Risk factor, Lung cancer, business.industry, Mortality rate, Cancer, Coronavirus Infections/epidemiology, Coronavirus Infections/mortality, Coronavirus Infections/pathology, Hospitalization/statistics & numerical data, Pneumonia, Viral/epidemiology, Pneumonia, Viral/mortality, Pneumonia, Viral/pathology, Registries/statistics & numerical data, Thoracic Neoplasms/epidemiology, Thoracic Neoplasms/mortality, Thoracic Neoplasms/pathology, Thoracic Neoplasms/therapy, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Human medicine, business, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], Cohort study
Abstract

Contains fulltext : 229846.pdf (Publisher’s version ) (Closed access) BACKGROUND: Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer treatments. We aimed to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with thoracic malignancies. METHODS: The Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry is a multicentre observational study composed of a cross-sectional component and a longitudinal cohort component. Eligibility criteria were the presence of any thoracic cancer (non-small-cell lung cancer [NSCLC], small-cell lung cancer, mesothelioma, thymic epithelial tumours, and other pulmonary neuroendocrine neoplasms) and a COVID-19 diagnosis, either laboratory confirmed with RT-PCR, suspected with symptoms and contacts, or radiologically suspected cases with lung imaging features consistent with COVID-19 pneumonia and symptoms. Patients of any age, sex, histology, or stage were considered eligible, including those in active treatment and clinical follow-up. Clinical data were extracted from medical records of consecutive patients from Jan 1, 2020, and will be collected until the end of pandemic declared by WHO. Data on demographics, oncological history and comorbidities, COVID-19 diagnosis, and course of illness and clinical outcomes were collected. Associations between demographic or clinical characteristics and outcomes were measured with odds ratios (ORs) with 95% CIs using univariable and multivariable logistic regression, with sex, age, smoking status, hypertension, and chronic obstructive pulmonary disease included in multivariable analysis. This is a preliminary analysis of the first 200 patients. The registry continues to accept new sites and patient data. FINDINGS: Between March 26 and April 12, 2020, 200 patients with COVID-19 and thoracic cancers from eight countries were identified and included in the TERAVOLT registry; median age was 68.0 years (61.8-75.0) and the majority had an Eastern Cooperative Oncology Group performance status of 0-1 (142 [72%] of 196 patients), were current or former smokers (159 [81%] of 196), had non-small-cell lung cancer (151 [76%] of 200), and were on therapy at the time of COVID-19 diagnosis (147 [74%] of 199), with 112 (57%) of 197 on first-line treatment. 152 (76%) patients were hospitalised and 66 (33%) died. 13 (10%) of 134 patients who met criteria for ICU admission were admitted to ICU; the remaining 121 were hospitalised, but were not admitted to ICU. Univariable analyses revealed that being older than 65 years (OR 1.88, 95% 1.00-3.62), being a current or former smoker (4.24, 1.70-12.95), receiving treatment with chemotherapy alone (2.54, 1.09-6.11), and the presence of any comorbidities (2.65, 1.09-7.46) were associated with increased risk of death. However, in multivariable analysis, only smoking history (OR 3.18, 95% CI 1.11-9.06) was associated with increased risk of death. INTERPRETATION: With an ongoing global pandemic of COVID-19, our data suggest high mortality and low admission to intensive care in patients with thoracic cancer. Whether mortality could be reduced with treatment in intensive care remains to be determined. With improved cancer therapeutic options, access to intensive care should be discussed in a multidisciplinary setting based on cancer specific mortality and patients' preference. FUNDING: None.

Published
2020

3. Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration

Author

Mountzios, G., primary, Remon, J., additional, Novello, S., additional, Blais, N., additional, Califano, R., additional, Cufer, T., additional, Dingemans, A.M., additional, Liu, S.V., additional, Peled, N., additional, Pennell, N.A., additional, Reck, M., additional, Rolfo, C., additional, Tan, D., additional, Vansteenkiste, J., additional, West, H., additional, and Besse, B., additional

Published
2019
Full Text
View/download PDF

5. OA08.02 A Multidisciplinary Multi-Omics Study of Spatial and Temporal Tumor Evolution in Thoracic Cancers with Clinical Implications

Author

Alcala, N., primary, Mangiante, L., additional, Poret, A., additional, Gabriel, A., additional, Derks, J., additional, Moonen, L., additional, Boyault, S., additional, Le Stang, N., additional, Ghantous, A., additional, Tabone-Eglinger, S., additional, Damiola, F., additional, Blay, J., additional, Mckay, J., additional, Dingemans, A.M., additional, Speel, E., additional, Caux, C., additional, Girard, N., additional, Lantuejoul, S., additional, Dayton, T., additional, Sallé, F. Galateau, additional, Fernandez-Cuesta, L., additional, and Foll, M., additional

Published
2019
Full Text
View/download PDF

6. MA08.02 Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey

Author

Levra, M. Giaj, primary, Benet, J., additional, Hasan, B., additional, Berghmans, T., additional, Bruni, A., additional, Dingemans, A.M., additional, Levra, N. Giaj, additional, Edwards, J., additional, Faivre-Finn, C., additional, Girard, N., additional, Gobbini, E., additional, Greillier, L., additional, Hendriks, L., additional, Lantuejoul, S., additional, Levy, A., additional, Novello, S., additional, O'Brien, M., additional, Reck, M., additional, Pochesci, A., additional, Menis, J., additional, and Besse, B., additional

Published
2019
Full Text
View/download PDF

9. MA07.02 Early Change of dNLR Is Correlated with Outcomes in Advanced NSCLC Patients Treated with Immunotherapy

Author

Mezquita, L., primary, Preeshagul, I., additional, Auclin, E., additional, Saravia, D., additional, Hendriks, L., additional, Rizvi, H., additional, Planchard, D., additional, Park, W., additional, Nadal, E., additional, Ruffinelli, J.C., additional, Ponce, S., additional, Audigier-Valette, C., additional, Carnio, S., additional, Novello, S., additional, Zalcman, G., additional, Majem, M., additional, Mariniello, A., additional, Dingemans, A.M., additional, Lopes, G., additional, Rossoni, C., additional, Pignon, J., additional, Chaput, N., additional, Hellmann, M., additional, Arbour, K., additional, and Besse, B., additional

Published
2019
Full Text
View/download PDF

10. Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

Author

Gadgeel, S., Shaw, A.T., Barlesi, F., Crino, L., Yang, J.C.H., Dingemans, A.M., Kim, D.W., de Marinis, F., Schulz, M., Liu, S.Y., Gupta, R., Smoljanovic, V., Ou, S.H.I., RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, and MUMC+: MA Med Staf Spec Longziekten (9)

Subjects
non-small-cell lung cancer, NP28673, NP28761, alectinib, time to response
Abstract

Introduction: Alectinib is a highly selective and potent ALK inhibitor, approved for the treatment of patients with metastatic ALK+ NSCLC based on results from the Phase II global NP28673 (NCT01801111) and North American NP28761 (NCT01871805) studies.Methods: This exploratory analysis of two Phase II studies of alectinib (NP28673/ NP28761) investigated time to systemic response (TTR) and time to central nervous system (CNS) response (TTCR) in patients with previously treated advanced anaplastic lymphoma kinase fusion gene-positive (ALK+) non-small-cell lung cancer. Patients (n=225) received 600 mg oral alectinib twice daily and had scans every 6/8 weeks (NP28673/NP28761).Results: For NP28673 and NP28761, respectively: median follow-up was 21.3 months/17.0 months; most responders (72.6%/82.9%) responded by the first disease assessment; median TTR was 8 weeks (95% confidence interval [CI]: 8.00-8.14)/6 weeks (95% CI: 5.86-6.14); median TTCR in responders with measurable baseline CNS disease was 8 weeks (95% CI: 7.86-10.29)/6 weeks (95% CI: 5.71-not evaluable). Similar results were observed regardless of measurable/non-measurable disease.Discussion: These data suggest that alectinib achieves a rapid response in patients, both systemically and in the CNS.

Published
2019

13. IMMUNOPROG : efficacité des inhibiteurs de point de contrôle immunitaire (ICI) chez des patients porteurs d’un carcinome bronchique non à petites cellules réfractaire à une chimiothérapie de première ligne

Author

Lefebvre, C., primary, Martin, E., additional, Veillon, R., additional, Puisset, F., additional, Hendriks, L., additional, Dingemans, A.M., additional, Besse, B., additional, Raherison, C., additional, and Mazières, J., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results